10x Genomics, Inc. (TXG)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 299 | 490 | 516 | 619 | 611 | 643 | 617 | 620 |
| Operating profit | $m | -111 | -88 | ||||||
| Net profit | $m | -543 | -58 | -166 | -255 | -183 | -44 | -75 | -92 |
| EPS reported | $ | -0.35 | -0.59 | ||||||
| Operating cashflow per share | $ | 1.09 | 0.98 | ||||||
| Capex per share | $ | 0.05 | 0.04 | ||||||
| FCF per share | $ | 1.04 | 0.93 | ||||||
| Free cash flow | $m | 130 | 121 | ||||||
| Net debt | $m | -439 | -552 | ||||||
| Book value equity | $m | 796 | 826 | ||||||
| Book value per share | $ | 6.38 | 6.35 | ||||||
| Number of shares | m | 124.75 | 129.98 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.56 | 2.46 | ||||||
| P/S LTM | x | 3.17 | 3.30 | ||||||
| P/FCF LTM | x | 15.64 | 16.76 | ||||||
| EV/EBITDA LTM | x | 439.61 | 61.36 | ||||||
| EV/Sales LTM | x | 2.67 | 11.33 | ||||||
| Earnings Yield LTM | % | -2.14% | -0.99% | ||||||
| FCF Yield | % | +6.39% | +5.97% | ||||||
| Quality | |||||||||
| ROE | % | -5.47% | -9.33% | ||||||
| ROIC | % | -12.34% | -9.57% | ||||||
| Operating margin | % | -17.25% | -14.33% | ||||||
| Gross margin | % | +69.05% | +70.03% | ||||||
| FCF/Sales | % | +20.24% | +19.68% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +5.25% | +1.00% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.82 | 1.54 | ||||||
| Net Debt/EBITDA | x | -80.90 | -15.13 | ||||||
| EBIT/Net interest | x | 0.00 | -29,461.33 | ||||||
| Net debt/market cap | % | +4.15% | 0.00% | ||||||
| Net debt/Equity | x | -0.55 | -0.67 | ||||||
| Gross debt/equity | x | 0.20 | 0.10 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free